Cancer Communications
indexed by SCI
BMC

Case report
Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
Giovanni Brandi, Michela Venturi, Stefania De Lorenzo, Francesca Garuti, Giorgio Frega, Andrea Palloni, Ingrid Garajovà, Francesca Abbati, Gioconda Saccoccio, Rita Golfieri, Maria Abbondanza Pantaleo and Maria Aurelia Barbera
Department of Experimental, Diagnostic and Specialty Medicine, St. Orsola-Malpighi Hospital, Haematological and Oncological Institute, University of Bologna, Bologna, Italy
[Abstract]

Background
Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death. Sorafenib, a multitarget angiogenesis inhibitor, is an approved frontline treatment for advanced HCC in Western countries, although a complete response (CR) to treatment is infrequently reported. Capecitabine, an oral fluoropyrimidine, has been shown to be effect in both treatment-naïve patients and those previously treated with sorafenib. To date, however, only one case of sustained CR to metronomic capecitabine has been reported.
Case presentation
We describe three cases of advanced HCC treated with metronomic capecitabine where a CR was obtained. In the first case, capecitabine was administered as first line therapy; in the second case, capecitabine was used after intolerance to sorafenib; while in the third case, capecitabine was administered after sorafenib failure.
Conclusion
Capecitabine is a potentially important treatment option for patients with advanced HCC and may even represent a cure in certain cases.
Cancer Communications   Epub date: 2018-6-26   doi:10.1186/s40880-018-0312-1   [ PDF Full-text ]   


 

Editorial Manager


CC adopts Editorial Manager to manage its submissions from Dec.18, 2014

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by BioMed Central

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China